New Weapons in the Fight Against Gonorrhea: What the FDA Approvals Mean for Tennessee and Beyond
The FDA’s recent approval of two new oral antibiotics – zoliflodacin (Nuzolvence) and gepotidacin (Blujepa) – marks a significant turning point in the treatment of gonorrhea, a sexually transmitted infection (STI) that’s becoming increasingly resistant to existing drugs. This news is particularly relevant for states like Tennessee, which currently experience higher rates of gonorrhea than the national average.
Tennessee’s Gonorrhea Rates and the Rise of Resistance
According to Dr. Schaffner, Professor of Infectious Diseases at Vanderbilt University Medical Center, Tennessee ranks in the top 25% of states for gonorrhea frequency. He emphasized that whereas antibiotic resistance hasn’t yet become a major issue within Tennessee, the global trend of gonorrhea becoming harder to treat is a serious concern. “The antibiotics aren’t working as well,” Dr. Schaffner explained. “It’s out there.”
Zoliflodacin: A First-of-Its-Kind Treatment
Zoliflodacin is a first-in-class antibiotic, meaning it’s the first drug in its class to target gonorrhea. It’s designed for oral suspension and offers a single-dose treatment option for uncomplicated urogenital gonorrhea in adults and pediatric patients weighing at least 35 kg. This is a major advantage, as adherence to multi-dose regimens can be challenging.
Blujepa: Expanding Treatment Options
Blujepa received supplemental FDA approval for treating gonorrhea and is available in oral tablet form for patients weighing at least 99 pounds. Clinical trials showed a 93% cure rate with Blujepa, comparable to the 91% cure rate achieved with standard treatment. This provides an alternative when other options are limited.
The Importance of Oral Medications and Single-Dose Regimens
Dr. Schaffner highlighted the benefits of oral administration and single-dose treatments. “If you can give it orally…That’s much more acceptable,” he stated. “Number two, if you can give it just in one dose…you can do the whole thing right then and there, completely, quickly, easily, and acceptability is then very high on the part of the patient.”
Understanding Gonorrhea’s Presentation in Men and Women
Awareness of symptoms is crucial for early detection and treatment. Dr. Schaffner explained that gonorrhea often presents differently in men and women. Men typically experience burning during urination and discharge, while women may be asymptomatic. He also noted that the infection can occur in the throat or anus and be silent in both sexes.
Accessibility and Regular Testing: Key to Control
Dr. Schaffner stressed the importance of accessibility to medication and regular testing. “If you’ve been with multiple partners, or you’re not sure of those partners, is always a good idea to get tested.”
Frequently Asked Questions
What is gonorrhea?
Gonorrhea is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae.
Why are these new drugs important?
Gonorrhea is becoming resistant to existing antibiotics, making treatment more difficult. These new drugs offer alternative options.
Are these drugs available now?
The FDA approved these drugs in December 2025. Availability may vary by location.
Should I get tested for gonorrhea?
If you are sexually active, especially with multiple partners, regular testing is recommended.
Pro Tip: Don’t hesitate to discuss STI testing with your healthcare provider. Early detection and treatment are vital for preventing complications and controlling the spread of infection.
Learn more about gonorrhea and STI prevention from the Centers for Disease Control and Prevention (CDC).
Did you know? Untreated gonorrhea can lead to more widespread infections and infertility.
Have questions about gonorrhea or these new treatments? Share your thoughts in the comments below!
